Evolution of the market for mRNA technology

Xie, Wen; Chen, Baiping; Wong, John W.

doi:10.1038/d41573-021-00147-y

Cited by 28 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The modified mRNA technology used in COVID-19 vaccines also holds great potential for therapeutic applications requiring controlled spatial and temporal delivery of paracrine factors such as VEGF-A 4 . This potential supported the investigation of VEGFA mRNA to induce therapeutic angiogenesis and proliferation in the context of heart disease 5 .…”

Section: Therapeutic Rationalementioning

confidence: 99%

VEGFA mRNA for regenerative treatment of heart failure

Collén

Bergenhem

Carlsson

et al. 2021

Nat Rev Drug Discov

View full text Add to dashboard Cite

Section: Therapeutic Rationalementioning

confidence: 99%

VEGFA mRNA for regenerative treatment of heart failure

Collén

Bergenhem

Carlsson

et al. 2021

Nat Rev Drug Discov

View full text Add to dashboard Cite

“…mRNA can be used as prophylactic vaccines, therapeutic vaccines or therapeutics [ 48 ]. Recently, the proof of principle of the mRNA technique was very successfully given by COVID-19 vaccines and VEGF mRNA for the regenerative treatment of heart failure [ 52 , 99 ].…”

Section: Bringing Intrabodies Into Cancer Patients: Delivery Of Intra...mentioning

confidence: 99%

“…The usage of engineered mRNA as prophylactic vaccines, therapeutic vaccines and therapeutics [ 48 ] represents a major breakthrough in efficient therapeutic drug delivery. The embedding of the mRNA in lipoprotein nanoparticles is very promising [ 49 ].…”

Section: Introductionmentioning

confidence: 99%

“…AAV vectors are the leading gene delivery platform for gene therapy with three gene therapy drugs approved by the European Medicines Agency and the United States Food and Drug Administration [44][45][46][47]. The usage of engineered mRNA as prophylactic vaccines, therapeutic vaccines and therapeutics [48] represents a major breakthrough in efficient therapeutic drug delivery. The embedding of the mRNA in lipoprotein nanoparticles is very promising [49].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions

Böldicke

2022

Antibodies

View full text Add to dashboard Cite

Tumor cells are characterized by overexpressed tumor-associated antigens or mutated neoantigens, which are expressed on the cell surface or intracellularly. One strategy of cancer immunotherapy is to target cell-surface-expressed tumor-associated antigens (TAAs) with therapeutic antibodies. For targeting TAAs or neoantigens, adoptive T-cell therapies with activated autologous T cells from cancer patients transduced with novel recombinant TCRs or chimeric antigen receptors have been successfully applied. Many TAAs and most neoantigens are expressed in the cytoplasm or nucleus of tumor cells. As alternative to adoptive T-cell therapy, the mRNA of intracellular tumor antigens can be depleted by RNAi, the corresponding genes or proteins deleted by CRISPR-Cas or inactivated by kinase inhibitors or by intrabodies, respectively. Intrabodies are suitable to knockdown TAAs and neoantigens without off-target effects. RNA sequencing and proteome analysis of single tumor cells combined with computational methods is bringing forward the identification of new neoantigens for the selection of anti-cancer intrabodies, which can be easily performed using phage display antibody repertoires. For specifically delivering intrabodies into tumor cells, the usage of new capsid-modified adeno-associated viruses and lipid nanoparticles coupled with specific ligands to cell surface receptors can be used and might bring cancer intrabodies into the clinic.

show abstract

“…Since its discovery in 1960, messenger RNA (mRNA) has attracted increasing attention in both basic and applied research [ 1 , 2 ]. With the increased understanding of the structure and function of mRNA, mRNA has been emerging as a promising therapeutic modality for the prevention or treatment of diseases ( Figure 1 ) [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Polyester materials for mRNA delivery

Chen

Liu

et al. 2022

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Messenger RNA (mRNA) has recently made important progress in clinical implementation, offering a promising therapeutic option for infectious disease and cancer. However, the nature of mRNA molecules rendered them poorly bioavailable and unstable in vivo, impeding their further clinical application. Therefore, safe and efficient delivery of mRNA therapeutics to the target site is crucial for their successful translation into the clinical setting. Various vectors have been explored for mRNA delivery. Among them, polyesters and their analogs, a family of biodegradable polymers, have exhibited great potential for mRNA delivery. In this short review, the authors briefly introduce mRNA therapeutics, their therapeutic applications and delivery challenges. The authors then presented the typical examples of polyester materials for mRNA delivery to highlight the current progress and discuss the challenges for the rational design of polyester based mRNA delivery vectors. The authors hope to provide a new insight for the design of biodegradable vectors for nucleic acids delivery, thereby promoting their further clinic translation.

show abstract

Evolution of the market for mRNA technology

Cited by 28 publications

References 0 publications

VEGFA mRNA for regenerative treatment of heart failure

VEGFA mRNA for regenerative treatment of heart failure

Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions

Polyester materials for mRNA delivery

Contact Info

Product

Resources

About